RRPV #NVP-Initiative_Coming-Soon

BARDA Seeks Advanced Vaccine Platform Technologies for Medical Countermeasures

This opportunity from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, seeks to advance new vaccine platform technologies for medical countermeasures. - Government Buyer: - Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health and Human Services - Scope and Requirements: - Soliciting proposals for the New Vaccine Platforms (NVP) Program - Open to single organizations or two-part teams providing a full technology solution (antigen expression and vaccine carrier/formulation) - In-scope technologies: protein-based, viral vector-based, and bacterial vector-based vaccine platforms - Technologies must have demonstrated manufacturing of Phase 1 clinical trial material - Staged capability demonstrations required across at least two emerging infectious disease threats - Example threats: Lassa virus, Nipah virus, chikungunya virus, West Nile virus - Additional options may include pandemic influenza and other CBRN-aligned threats - Focus on platforms that are safe, broadly protective, and enable streamlined development and manufacturing - OEMs and Vendors: - No specific OEMs or vendors are named in the notice - Unique/Notable Requirements: - Emphasis on full platform solutions, not just individual components - Demonstration of manufacturing readiness for clinical trial material - Flexibility to address multiple infectious disease threats - Place of Performance/Delivery: - BARDA (federal office) is the contracting authority

Description

The New Vaccine Platforms (NVP) Program seeks to identify and advance new vaccine platforms for the BARDA medical countermeasure portfolio. The program focuses on technologies that are safe, effective across multiple infectious disease threats, and enable efficient development and manufacturing. Eligible proposals may come from single organizations or two-part teams offering a full technology solution. The program includes staged capability demonstrations across at least two emerging infectious disease threats such as Lassa virus, Nipah virus, chikungunya virus, or West Nile virus.

View original listing